Bittner S, Höhn K, Göbel K, Kleinschnitz C, Wiendl H, Meuth S G
Abteilung für entzündliche Erkrankungen des Nervensystems und Neuroonkologie, Klinik und Poliklinik für Neurologie, Universitätsklinikum Münster, Domagkstr. 13, 48149 Münster, Deutschland.
Nervenarzt. 2011 Oct;82(10):1273-80. doi: 10.1007/s00115-011-3321-8.
Due to a plethora of additional symptoms patients with multiple sclerosis (MS) receive symptomatic treatment besides disease-modifying therapies. Among the substances which are commonly used are ion channel modulators (e. g. pregabalin, gabapentin, carbamazepine). The aim of this study was to investigate the use of these drugs in clinical practice in a larger patient cohort.
Data from 533 MS patients [439 without and 94 patients with add-on therapy (treatment group)] were evaluated retrospectively. All patients received a detailed neurological examination including evaluation of EDSS scores.
Pregabalin and gabapentin are used most commonly. Abnormal sensations are the most frequent reason for therapy initiation. Patients with higher EDSS values and/or under mitoxantrone treatment most frequently receive additional therapy.
So far, it is not known whether the investigated agents exert a beneficial influence on the disease course of MS itself beyond a mere symptomatic treatment. Further research efforts and clinical studies are necessary to address this question.
由于多发性硬化症（MS）患者存在大量其他症状，除了疾病修饰疗法外，他们还接受对症治疗。常用的药物包括离子通道调节剂（如普瑞巴林、加巴喷丁、卡马西平）。本研究的目的是在更大的患者队列中调查这些药物在临床实践中的使用情况。
对533例MS患者的数据进行了回顾性评估[439例未接受附加治疗，94例接受附加治疗（治疗组）]。所有患者均接受了详细的神经系统检查，包括扩展残疾状态量表（EDSS）评分评估。
普瑞巴林和加巴喷丁使用最为普遍。感觉异常是开始治疗的最常见原因。EDSS值较高和/或接受米托蒽醌治疗的患者最常接受附加治疗。
到目前为止，尚不清楚所研究的药物除了单纯的对症治疗外，是否对MS本身的病程有有益影响。需要进一步的研究和临床研究来解决这个问题。
